Get the Stockscreener App
21.76
1.18%
-0.26
After Hours:
21.71
-0.05
-0.23%
Acadia Pharmaceuticals Inc stock is traded at $21.76, with a volume of 1.23M.
It is down -1.18% in the last 24 hours and up +5.58% over the past month.
Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on turning scientific promise to makes a difference for underserved neurological and rare disease communities around the world. It has two core franchises in neurological and rare diseases. Its neurological disease is anchored by the commercial product NUPLAZID (pimavanserin), which is the first and only drug approved by the U.S. (FDA) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis (PDP). Its rare disease is anchored by the commercial product DAYBUE, which is the first and only drug approved for the treatment of Rett syndrome. Its clinical-stage development efforts are focused on Alzheimer's disease psychosis, Lewy Body Dementia psychosis, and multiple other programs.
See More
Previous Close:
$22.02
Open:
$22.02
24h Volume:
1.23M
Relative Volume:
0.75
Market Cap:
$3.71B
Revenue:
$1.07B
Net Income/Loss:
$391.00M
P/E Ratio:
9.5088
EPS:
2.2884
Net Cash Flow:
$6.31M
1W Performance:
-3.55%
1M Performance:
+5.58%
6M Performance:
+0.09%
1Y Performance:
+45.16%
1-Day Range:
$21.72
$22.32
1-Week Range:
$20.96
$22.66
52-Week Range:
$14.08
$28.35
Acadia Pharmaceuticals Inc Stock (ACAD) Company Profile
Name
Acadia Pharmaceuticals Inc
Sector
Industry
Phone
858-558-2871
Address
12830 EL CAMINO REAL, SAN DIEGO
Compare ACAD vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ACAD
Acadia Pharmaceuticals Inc
|
21.76 | 3.75B | 1.07B | 391.00M | 6.31M | 2.2884 |
VRTX
Vertex Pharmaceuticals Inc
|
441.70 | 113.01B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
753.93 | 79.87B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
840.87 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
333.39 | 45.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
319.94 | 34.41B | 5.36B | 287.73M | 924.18M | 2.5229 |
Acadia Pharmaceuticals Inc Stock (ACAD) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-25-26 | Upgrade | BofA Securities | Neutral → Buy |
| Feb-24-26 | Initiated | Wolfe Research | Outperform |
| Feb-23-26 | Upgrade | Mizuho | Neutral → Outperform |
| Oct-21-25 | Initiated | Citigroup | Buy |
| May-21-25 | Upgrade | Deutsche Bank | Hold → Buy |
| Feb-11-25 | Initiated | Deutsche Bank | Hold |
| Jan-03-25 | Downgrade | Guggenheim | Buy → Neutral |
| Oct-10-24 | Resumed | Raymond James | Mkt Perform |
| Aug-07-24 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jun-27-24 | Initiated | BMO Capital Markets | Outperform |
| Mar-12-24 | Downgrade | Mizuho | Buy → Neutral |
| Mar-12-24 | Reiterated | Needham | Buy |
| Jan-30-24 | Initiated | Robert W. Baird | Outperform |
| Jan-24-24 | Upgrade | Needham | Hold → Buy |
| Dec-19-23 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Dec-14-23 | Downgrade | Deutsche Bank | Buy → Hold |
| Dec-13-23 | Initiated | Citigroup | Buy |
| Dec-12-23 | Initiated | Deutsche Bank | Buy |
| Nov-06-23 | Upgrade | Mizuho | Neutral → Buy |
| Oct-17-23 | Initiated | UBS | Buy |
| Oct-10-23 | Upgrade | JP Morgan | Neutral → Overweight |
| Jan-03-23 | Upgrade | Guggenheim | Neutral → Buy |
| Nov-04-22 | Downgrade | Goldman | Neutral → Sell |
| Nov-01-22 | Initiated | Loop Capital | Hold |
| Aug-08-22 | Downgrade | Citigroup | Buy → Neutral |
| Aug-05-22 | Downgrade | Citigroup | Buy → Neutral |
| Jun-21-22 | Downgrade | Jefferies | Buy → Underperform |
| Jun-16-22 | Upgrade | Jefferies | Hold → Buy |
| Mar-16-22 | Upgrade | Canaccord Genuity | Hold → Buy |
| Feb-09-22 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Jan-05-22 | Upgrade | Citigroup | Neutral → Buy |
| Dec-21-21 | Downgrade | Guggenheim | Buy → Neutral |
| Nov-01-21 | Upgrade | Guggenheim | Neutral → Buy |
| Oct-14-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Sep-23-21 | Resumed | Needham | Hold |
| Jun-10-21 | Initiated | Berenberg | Hold |
| Apr-07-21 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Apr-06-21 | Downgrade | Canaccord Genuity | Buy → Hold |
| Apr-06-21 | Downgrade | Goldman | Buy → Neutral |
| Apr-06-21 | Downgrade | Jefferies | Buy → Hold |
| Apr-06-21 | Downgrade | Mizuho | Buy → Neutral |
| Apr-05-21 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Mar-10-21 | Downgrade | BofA Securities | Buy → Neutral |
| Mar-09-21 | Downgrade | Citigroup | Buy → Neutral |
| Mar-09-21 | Downgrade | Guggenheim | Buy → Neutral |
| Mar-09-21 | Reiterated | H.C. Wainwright | Buy |
| Mar-09-21 | Downgrade | Raymond James | Strong Buy → Outperform |
| Mar-09-21 | Downgrade | Stifel | Buy → Hold |
| Dec-16-20 | Initiated | Mizuho | Buy |
| Nov-16-20 | Upgrade | Raymond James | Outperform → Strong Buy |
| Aug-25-20 | Initiated | Raymond James | Outperform |
| Aug-20-20 | Initiated | Morgan Stanley | Overweight |
| Jul-07-20 | Upgrade | Stifel | Hold → Buy |
| Apr-16-20 | Initiated | Jefferies | Buy |
| Mar-31-20 | Upgrade | Goldman | Neutral → Buy |
| Mar-06-20 | Initiated | Citigroup | Buy |
| Dec-16-19 | Initiated | Guggenheim | Buy |
| Oct-24-19 | Initiated | Oppenheimer | Perform |
| Oct-01-19 | Initiated | RBC Capital Mkts | Outperform |
| Sep-13-19 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Sep-10-19 | Upgrade | Canaccord Genuity | Hold → Buy |
| Jul-23-19 | Reiterated | Needham | Buy |
| Dec-10-18 | Initiated | Canaccord Genuity | Hold |
| Sep-21-18 | Upgrade | Piper Jaffray | Neutral → Overweight |
| Aug-09-18 | Reiterated | Stifel | Hold |
| Aug-07-18 | Initiated | Stifel | Hold |
| Aug-06-18 | Downgrade | Piper Jaffray | Overweight → Neutral |
| Oct-06-17 | Resumed | Goldman | Neutral |
View All
Acadia Pharmaceuticals Inc Stock (ACAD) Latest News
ACADIA Pharmaceuticals stock (US0042251084): Is the next product pipeline now the real test for sust - AD HOC NEWS
Acadia launches powder version of Rett syndrome treatment in the US - MSN
ACADIA Pharmaceuticals Announces Advancement by Allergan of Novel Glaucoma Compound into Preclinical - Yahoo
ACAD Stock Price, Quote & Chart | ACADIA PHARMACEUTICALS INC (NASDAQ:ACAD) - ChartMill
Does ACADIA Pharmaceuticals Inc stock reflect fundamentals2026 Chart Watch & High Accuracy Trade Signal Alerts - baoquankhu1.vn
Breakout Watch: What is the target price for ACADIA Pharmaceuticals Inc stockWeekly Profit Recap & Technical Pattern Based Signals - baoquankhu1.vn
ACADIA Pharmaceuticals Inc. (ACAD) stock price, news, quote and history - Yahoo Finance Singapore
ACADIA Pharmaceuticals Insider Sells Over $22,000 in Stock - National Today
ACAD Stock Chart | ACADIA PHARMACEUTICALS INC (NASDAQ:ACAD) - ChartMill
Neuren Pharmaceuticals advances Rett syndrome treatment with US launch of DAYBUE STIX - BioMelbourne Network
Sectors Review: Is ACADIA Pharmaceuticals Inc being accumulated by smart money2026 Biggest Moves & AI Driven Price Forecasts - baoquankhu1.vn
(ACAD) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
Acadia Pharma EVP Schneyer sells $60k in stock By Investing.com - Investing.com Australia
Acadia Pharmaceuticals officer sells $22,866 in stock By Investing.com - Investing.com Australia
Acadia Pharmaceuticals officer sells $22,866 in stock - Investing.com
Acadia Pharma EVP Schneyer sells $60k in stock - Investing.com
[Form 4] ACADIA PHARMACEUTICALS INC Insider Trading Activity - Stock Titan
Acadia (NASDAQ: ACAD) officer sells shares to cover RSU tax obligations - Stock Titan
Acadia Pharmaceuticals Launches DAYBUE STIX for Rett Syndrome - National Today
Acadia Pharmaceuticals (ACAD) Expands Access to Rett Syndrome Tr - GuruFocus
Acadia Pharmaceuticals Announces DAYBUE® STIX (trofinetide) is Now Broadly Available in the United States for the Treatment of Rett Syndrome - Bakersfield.com
User - The Chronicle-Journal
RBC Capital Adjusts ACADIA Pharmaceuticals PT to $29 From $30, Maintains Outperform Rating - Moomoo
ACADIA Pharmaceuticals Inc. (ACAD.MX) Income Statement - Yahoo! Finance Canada
Advantage Alpha Capital Partners LP's ACADIA Pharmaceuticals Inc(ACAD) Holding History - GuruFocus
IPO Launch: Is ACADIA Pharmaceuticals Inc being accumulated by smart money2026 Growth vs Value & Technical Confirmation Alerts - baoquankhu1.vn
ACADIA Pharmaceuticals Inc. $ACAD Shares Bought by Allspring Global Investments Holdings LLC - MarketBeat
A Look At ACADIA Pharmaceuticals (ACAD) Valuation As Shares Trade Near Recent Levels - Yahoo Finance
ACADIA Pharmaceuticals Inc. (ACAD) Stock forecasts - Yahoo Finance UK
ACAD PE Ratio & Valuation, Is ACAD Overvalued - Intellectia AI
Which Is a Better Investment, ACADIA Pharmaceuticals Inc. or Relay Therapeutics, Inc. Stock? - AAII
Insiders At ACADIA Pharmaceuticals Sold US$1.0m In Stock, Alluding To Potential Weakness - 富途牛牛
ACADIA Pharmaceuticals Inc (DR6.SG) Analyst insights, Price targets and Recommendations - Yahoo Finance UK
ACADIA Pharmaceuticals Inc. (ACAD) Stock Forecasts - Yahoo Finance
Glioblastoma Pipeline 2026: Key Companies, MOA, ROA, and Clinical Trials Evaluation by DelveInsight | InovioPharma, Pfizer, Roche, ACADIA Pharma, BioNTech, Oncotelic Therapeutics, Autotelic Therapeuti - Barchart
BofA Securities Lifts ACADIA Pharmaceuticals Inc. (ACAD)’s Price Target To $23, Maintains Neutral Rating - MSN
Layoff Watch: Is ACADIA Pharmaceuticals Inc being accumulated by smart moneyStop Loss & Fast Entry and Exit Trade Plans - baoquankhu1.vn
Update Recap: Can ACADIA Pharmaceuticals Inc continue delivering strong returns - baoquankhu1.vn
Acadia Pharmaceuticals stock drops 3.35% as company gears up for post-acute care conference - Traders Union
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat
A Look At ACADIA Pharmaceuticals (ACAD) Valuation After Recent Mixed Share Performance - simplywall.st
Acadia Pharma EVP Schneyer sells $159k in stock By Investing.com - Investing.com Australia
Acadia Pharma EVP Schneyer sells $159k in stock - Investing.com UK
Acadia Pharmaceuticals exec sells $41,895 in stock By Investing.com - Investing.com India
Acadia Pharmaceuticals exec sells $41,895 in stock - Investing.com
Acadia EVP Thompson sells $73k in stock after option exercise - Investing.com
Acadia EVP Rhodes sells $82k in stock after option exercise - Investing.com
Acadia Pharma CEO Owen Adams Catherine sells $249k in stock - Investing.com
Acadia Pharma CEO Owen Adams Catherine sells $249k in stock By Investing.com - Investing.com India
Acadia EVP Rhodes sells $82k in stock after option exercise By Investing.com - Investing.com South Africa
ACADIA (NASDAQ: ACAD) officer sells 1,942 shares after RSU vesting - Stock Titan
Acadia Pharmaceuticals Inc Stock (ACAD) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.69%
0.25%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):